Breaking Down Jupiter Wellness, Inc. (JUPW) Financial Health: Key Insights for Investors

Investors scanning microcap opportunities should take a close look at Jupiter Wellness, Inc. (JUPW), trading at $0.3917 per share with a -$0.03 (-0.07%) move, an intraday high/low of $0.439 / $0.3703, volume of 13,958,898 and last trade on Thursday, October 9 at 17:15 PDT, while the company reported just $2.8 million in revenue for fiscal 2022-75% of which came from three product lines-and a net loss of -$15.22 million (net margin -25%), with EBIT of -$12.92 million and EBITDA of -$9.84 million; balance-sheet reads include $13.16 million in cash and cash equivalents, market capitalization of $41.73 million (enterprise value reported at $41.85M in Nov 2025 and $34.74M TTM), zero long-term debt but a deeply negative ROE of -162.95% and interest coverage of -10.80, while management projects revenue of $25 million and EBIT of $10 million by 2025 amid heavy R&D ($2.1M) and marketing ($3.5M) spend-do these stark liquidity figures, concentrated product revenue streams, and upside projections warrant deeper due diligence?

Jupiter Wellness, Inc. (JUPW) - Revenue Analysis

• Equity listing: USA market (ticker: JUPW)
• Latest price: $0.3917 (change: -$0.03, -0.07% vs. previous close)
• Latest trade time: Thursday, October 9, 17:15:00 PDT

• Public revenue disclosure: Most recent published financial statements should be consulted for official top-line figures (investors should verify latest 10-Q/10-K filings).
• Common revenue-driven KPIs for analysis:
  • Year-over-year revenue growth - requires latest quarterly/annual report.
  • Revenue per share - calculated from reported revenue ÷ diluted shares outstanding.
  • Gross margin and operating margin - needed to assess sustainability of revenue.
• Near-term market signals: low per-share price ($0.3917) and elevated intraday volume (13.96M) can indicate high retail trading interest or volatility that may precede material corporate disclosures affecting revenue outlook.

• Practical next steps for investors focused on revenue:
  • Review the latest 10-Q/10-K for reported revenue, margins, and segment disclosures.
  • Compare reported revenue against historical quarters to measure growth trend.
  • Monitor press releases for product launches, partnerships, or contracts that could drive near-term revenue.

Jupiter Wellness, Inc. (JUPW) - Profitability Metrics

• High product concentration: ~75% of 2022 revenue from three product lines increases operational and market risk.
• Declining legacy product sales: outdated skincare fell 25% year-over-year, from $1.6M to $1.2M.
• New product underperformance: therapeutic CBD skincare generated ~$500K versus initial $1.2M expectation (shortfall ~$700K).
• Gadget expectations missed: wellness gadgets produced $250K in 2022 against a $750K target, signaling go-to-market or demand issues.
• Aggressive growth targets: management projects revenue rising to $25M by 2025 with $10M EBIT-implying substantial scale-up and margin expansion from current levels.

• Revenue runway: moving from $2.8M to $25M in three years requires sustained customer acquisition, product diversification, and likely increased SG&A and capex.
• Margin credibility: a projected 40% EBIT margin (10M / 25M) is ambitious for consumer wellness without clear evidence of scalable gross margins and operating leverage.
• Concentration risk mitigation needed: diversification beyond the top three lines is essential to stabilize revenue and support valuation multiple expansion.
• Forecast sensitivity: shortfalls in new product adoption (CBD skincare, gadgets) materially affect near-term cash flow and ability to fund growth internally.

Jupiter Wellness, Inc. (JUPW) - Debt vs. Equity Structure

• Net profit margin (FY2022): -25%, indicating the company lost $0.25 for every dollar of revenue in 2022.
• EBIT (FY2022): -$12.92 million - operating profit before interest and taxes was negative, limiting internal cash generation for servicing debt.
• EBITDA (FY2022): -$9.84 million - core operating cash performance remains negative even before non-cash charges.
• Net income (FY2022): -$15.22 million - after all items, the company posted a material loss.

• Negative EBITDA and sustained losses reduce capacity to take on additional debt without material covenant stress or higher interest costs.
• Deeply negative ROE (-162.95% TTM) compared with a historical average of 275% signals equity returns have swung from highly positive to severe erosion - equity holders face dilution risk if the company issues shares to shore liquidity.
• Negative P/E (-0.45) reflects the absence of positive earnings; market pricing implies equity valuation is driven by expectations of recovery, not current earnings power.
• Lenders will likely demand tighter covenants, higher spreads, or collateral; management may prefer equity-based financing despite dilution to avoid restrictive debt terms.

• Short-term financing needs should be benchmarked against projected cash burn derived from EBITDA and net income trends; with FY2022 EBITDA at -$9.84M and net loss of -$15.22M, runway relies on either operating improvements or new capital.
• Leverage ratios based on recent losses will appear elevated or meaningless (negative equity returns); stress-testing scenarios should assume muted revenue growth with gradual margin recovery to break-even.
• Investor sensitivity: equity investors must price in turnaround probability; debt investors must price in recovery risk and potential recovery via secured claims.

Jupiter Wellness, Inc. (JUPW) - Liquidity and Solvency

• Market capitalization (Nov 2025): $41.73 million
• Enterprise value (Nov 2025): $41.85 million
• Total equity: $41.73 million
• Total debt: $0

Key liquidity and solvency takeaways for investors:

• Zero reported total debt and a debt-to-equity ratio of 0.00 indicate Jupiter Wellness, Inc. (JUPW) is currently unlevered, reducing financial risk tied to interest-bearing obligations.
• The interest coverage ratio of -10.80 signals negative EBIT - operating earnings are insufficient to cover interest expense, which may reflect operating losses or one-time charges; in an unlevered capital structure this is largely academic but flags operating profitability concerns.
• The debt service coverage ratio of 288.16 is anomalously high because debt service demand is effectively zero; this metric should be treated cautiously and not as a standalone sign of strength.
• Enterprise value slightly exceeds market cap by ~$0.12 million, suggesting minor non-equity adjustments (e.g., cash, leases, or other non-debt items) affecting EV calculation.

Relevant corporate context and forward-looking references can be found here: Mission Statement, Vision, & Core Values (2026) of Jupiter Wellness, Inc.

Jupiter Wellness, Inc. (JUPW) - Valuation Analysis

Liquidity and solvency metrics are central to assessing Jupiter Wellness, Inc. (JUPW)'s short-term resilience and longer-term financial stability. The following section parses key ratios and cash-flow items from fiscal year 2025 to inform valuation inputs and risk assessment.

• Current ratio: 1.94 - indicates the company holds $1.94 in current assets for every $1.00 of current liabilities, providing a comfortable short-term buffer versus many industry peers.
• Quick ratio: 1.69 - shows strong coverage of near-cash obligations when inventories and less liquid current assets are excluded.
• Cash and cash equivalents (FY2025 year-end): $13.16 million - usable liquidity available for operations, working capital needs, and near-term obligations.
• Net cash from operating activities (FY2025): $759,120 - positive operating cash flow, though modest relative to balance-sheet scale and financing outflows.
• Net cash used in financing activities (FY2025): $19.71 million - significant financing outflow that materially affected liquidity.
• Net decrease in cash and cash equivalents (FY2025): $5.92 million - reflects the net impact of operating, investing and financing cash flows on year-end cash.

Key valuation implications:

• Positive, though limited, operating cash flow ( $759,120 ) suggests earnings-to-cash conversion is occurring but may not yet support large reinvestment or dividend initiatives without external funding.
• Substantial financing outflows ( $19.71 million ) can increase leverage risk or indicate capital structure reshaping-both material to discount-rate selection and terminal-value assumptions in DCF models.
• Year-end cash of $13.16 million and a current ratio of 1.94 reduce immediate solvency concerns, supporting nearer-term liquidity cushions used in scenario and stress testing.
• The net decrease in cash ( $5.92 million ) should be modeled into short-term liquidity forecasts and rolling covenant assessments for lenders or credit-rating considerations.

For broader context on company history, ownership and business model-factors that affect long-term cash generation assumptions-see: Jupiter Wellness, Inc. (JUPW): History, Ownership, Mission, How It Works & Makes Money

Jupiter Wellness, Inc. (JUPW) - Risk Factors

• Fair value (Peter Lynch) as of Nov 7, 2025: -$2.77 - indicates negative valuation under that metric (Peter Lynch formula).
• Relative valuation (P/E multiples) as of Jul 31, 2025: -$8.01 - negative P/E-based relative value.
• Enterprise Value (TTM) as of Nov 2025: $34.74 million.
• Market Capitalization as of Nov 2025: $41.73 million.
• Price-to-Sales (P/S): 6.03.
• Price-to-Book (P/B): 7.15.

• Negative Peter Lynch and P/E-derived valuations suggest earnings or growth inputs produced mathematically invalid/negative intrinsic values under those models; investors should verify underlying EPS, growth, and accounting adjustments.
• High P/S (6.03) and P/B (7.15) indicate the market is pricing a substantial premium on sales and book value relative to peers or historical norms.
• EV ($34.74M) vs. Market Cap ($41.73M) implies net cash or minority liability position affecting takeover or enterprise-level comparisons; reconcile with balance sheet cash/debt for clarity.

• Earnings volatility - negative P/E signals potential recent losses or one-time items; sensitivity to small EPS changes is high.
• Growth expectations priced in - elevated P/S and P/B ratios require continued revenue expansion and margin improvement to justify valuation.
• Liquidity and float - small market cap raises liquidity risk and amplifies price moves from limited trading volume.
• Model sensitivity - reliance on specific valuation formulas (Peter Lynch, P/E) can produce divergent outputs; cross-check with DCF and sector multiples.
• Balance sheet hidden items - reconcile EV vs. market cap with cash, short-term borrowings, and contingent liabilities.
• Market sentiment risk - premium multiples make share price vulnerable to changes in investor sentiment or macroeconomic shifts.

• Quarterly EPS trajectory and adjusted earnings to understand negative P/E drivers.
• Revenue growth rate and gross margin trends to support current P/S level.
• Book value change and tangible equity movements relative to the P/B multiple.
• Net debt/cash position reconciliation with EV and market cap.
• Share issuance or dilution events that can materially affect per-share metrics.

Jupiter Wellness, Inc. (JUPW) - Growth Opportunities

• Concentration risk: Jupiter Wellness depends heavily on a small set of core products (top 3 SKUs represent ~58% of 2022 revenue). A shift in consumer preferences or adverse regulatory action on any of these SKUs could materially depress top-line and margins.
• Limited scale vs. industry leaders: Estimated market share in the core supplement/wellness segment is roughly 0.2%, leaving JUPW exposed to price and promotional pressure from larger competitors with deeper distribution and purchasing power.
• Brand-recognition gap: Measured brand-awareness metrics show JUPW trailing key peers; customer acquisition costs are elevated and retention rates are below category averages, hampering lifetime value.
• Profitability strain from high spend: Heavy R&D and marketing investments drove a net profit margin of -25% in FY2022, reflecting aggressive product development and go-to-market spending ahead of scaling revenue.
• Inventory and cash-trap issues: Accumulated excess inventory tied to discontinued or underperforming lines represents a large portion of the company's working-capital strain and contributes to liquidity pressure.
• Underperforming hardware/gadget revenue: Wellness gadgets generated only $250,000 in 2022 versus an expected $750,000 - a 67% shortfall that underscores product-market fit and channel challenges.

• Working capital pressure: Elevated inventory ($2.1M) and higher marketing spend compress liquidity and increase the need for either external financing or rapid inventory monetization.
• Margin recovery dependency: Return to positive net margins requires either meaningful revenue growth (+30-50% target), gross margin expansion (target +5-8 pts), or material reductions in R&D/marketing intensity.
• Product diversification risk/need: Heavy reliance on a few SKUs calls for either expansion of stable product lines or strategic partnerships/licensing to reduce single-product exposure.
• Channel and go-to-market adjustments: Underperforming gadget line and weak brand traction imply a pivot to higher-conversion channels, improved pricing strategy, or reengineering of product positioning.

• Inventory remediation: Execute targeted promotions, bundle offers, and B2B liquidation to convert ~$2.1M of excess stock into cash and reduce carrying costs.
• Rationalize R&D/marketing spend: Reprioritize projects with the fastest path to margin contribution; consider pausing low-probability R&D and reallocating to direct-response marketing with strong ROI tracking.
• Focus on high-velocity SKUs: Double-down on the top-performing 20% of SKUs that drive ~70% of gross profit; accelerate replenishment and retailer placement for those items.
• Strategic partnerships and channels: Seek co-branding, subscription partnerships, or retail distribution agreements to amplify brand reach without proportionally higher CAC.
• Exit or reposition low-traction gadgets: Given $250k in 2022 gadget revenue vs. $750k expectation, consider divestiture, licensing, or a relaunch with validated customer feedback before further investment.

• Track quarterly improvements in inventory turnover and gross margin.
• Monitor R&D and marketing as a percentage of revenue - target a decline toward single-digit growth of spend relative to sales as scale improves.
• Watch gadget revenue trajectory and KPIs: customer acquisition cost (CAC), repeat purchase rate, and average order value (AOV).
• Assess potential dilution or financing events if negative operating cash flow persists beyond two consecutive quarters.